The truth about AI in drug discovery: what the experts really think
Sponsored by 
Merck2026-03-11T14:00:00
AI is transforming drug discovery - but beyond the hype, what’s actually delivering results? In this expert-led webinar, industry leaders explore where AI is accelerating target identification, molecule design and hit discovery, while also confronting the real-world challenges of data quality, validation and adoption. Discover what’s working today, what still ...
Artificial intelligence (AI) is moving fast in early drug discovery, but results are mixed and real progress is not always visible. This roundtable brings together experts working with AI in active programmes to discuss how it supports target selection, generative molecule design and rapid hit discovery, as well as how they address complex and incomplete data in practical settings. The panel will also explore what is emerging next, including AI twins, model-driven decision making and workflow automation, with open insight into what is working and where challenges remain.
Attendees will gain practical insight into current capability, the gaps that still slow teams down and what to expect in the next phase of AI adoption.
You will learn:
- Where AI is delivering value in target selection, generative design and hit discovery today
- What strong AI-enabled workflows look like in real discovery environments
- Current limitations, roadblocks and what still needs solving
- How AI twins, automation and model-driven decisions could change the next phase of R&D
- What teams must have in place to make AI adoption successful